Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Chief Financial Officer | October 18, 2024 | October 21, 2024 |
| Obsidian Therapeutics, Inc.OBX · Entity 4898 | Chief Financial Officer | August 03, 2026 | August 03, 2026 |
| Verastem, Inc.VSTM · Entity 5242 | Chief Financial Officer | April 06, 2018 | June 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date October 18, 2024 · Filed October 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,276 |
Ending reported balance
After 2024-10-18 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-10-18 · Exercise / conversion · Acquired 17,500 · Balance 151,776 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. Row 2 · 2024-10-18 · Exercise / conversion · Acquired 2,631 · Balance 154,407 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. Row 3 · 2024-10-18 · Exercise / conversion · Acquired 5,000 · Balance 159,407 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. Row 4 · 2024-10-18 · Sale · Disposed 25,131 · Balance 134,276 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2028-10-03 | Direct | 68,257 |
Reported balance
After 2024-10-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-10-18 · Exercise / conversion · Disposed 17,500 · Balance 68,257 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F3: This option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2030-03-16 | Direct | 32,359 |
Reported balance
After 2024-10-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-10-18 · Exercise / conversion · Disposed 2,631 · Balance 32,359 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F3: This option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.48 · Expires 2031-06-28 | Direct | 120,547 |
Reported balance
After 2024-10-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-10-18 · Exercise / conversion · Disposed 5,000 · Balance 120,547 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F4: The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This option is fully vested.
F4: The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021.
Obsidian Therapeutics, Inc.
Report date August 03, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2036-01-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-03 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 25% of the shares underlying this option shall vest and become exercisable on January 12, 2027, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2036-01-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-03 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 50% of the shares underlying this option shall vest and become exercisable on September 30, 2026, with the remainder vesting in eight (8) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option shall vest and become exercisable on January 12, 2027, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2: 50% of the shares underlying this option shall vest and become exercisable on September 30, 2026, with the remainder vesting in eight (8) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Verastem, Inc.
Report date April 06, 2018 · Filed June 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2028-01-05 | Direct | 5,000 |
Reported balance
After 2018-04-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-06 · Grant · Acquired 5,000 · Balance 5,000 F1: On January 5, 2018, the Reporting Person was granted an option to purchase 25,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 5,000 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 5, 2018, the Reporting Person was granted an option to purchase 25,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 5,000 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2024 Filed Oct 21, 2024 22:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0000950170-24-116029 · ownership.xml · derivative · entry 7 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,547 Underlying: Common Stock · 5,000 shares Expires 2031-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021. Read SEC document |
| October 18, 2024 Filed Oct 21, 2024 22:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,631 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0000950170-24-116029 · ownership.xml · derivative · entry 6 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,359 Underlying: Common Stock · 2,631 shares Expires 2030-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 18, 2024 Filed Oct 21, 2024 22:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-24-116029 · ownership.xml · derivative · entry 5 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,257 Underlying: Common Stock · 17,500 shares Expires 2028-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 18, 2024 Filed Oct 21, 2024 22:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 25,131 | $12.03 | $302,361.11 |
DisclosureSEC source: 0000950170-24-116029 · ownership.xml · nonDerivative · entry 4 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,276 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2024 Filed Oct 21, 2024 22:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 5,000 | $5.48 | $27,400.00 |
DisclosureSEC source: 0000950170-24-116029 · ownership.xml · nonDerivative · entry 3 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. Read SEC document |
| October 18, 2024 Filed Oct 21, 2024 22:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 2,631 | $4.25 | $11,181.75 |
DisclosureSEC source: 0000950170-24-116029 · ownership.xml · nonDerivative · entry 2 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. Read SEC document |
| October 18, 2024 Filed Oct 21, 2024 22:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 17,500 | $2.74 | $47,950.00 |
DisclosureSEC source: 0000950170-24-116029 · ownership.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:01 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 103,715 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000950170-24-010462 · ownership.xml · derivative · entry 2 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,715 Underlying: Common Stock · 103,715 shares Expires 2034-01-31 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:01 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 71,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-010462 · ownership.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,276 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2025, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 21:18 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 6,609 | $7.64 | $50,521.18 |
DisclosureSEC source: 0000950170-24-006987 · ownership.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,991 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.64 to $7.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 23:09 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,900 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-23-060493 · ownership.xml · derivative · entry 3 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,757 Underlying: Common Stock · 3,900 shares Expires 2028-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 23:09 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 3,900 | $12.07 | $47,053.89 |
DisclosureSEC source: 0000950170-23-060493 · ownership.xml · nonDerivative · entry 2 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,600 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 23:09 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 3,900 | $2.74 | $10,686.00 |
DisclosureSEC source: 0000950170-23-060493 · ownership.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 22:24 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 3,385 | $6.82 | $23,090.78 |
DisclosureSEC source: 0000950170-23-057643 · ownership.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,600 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.80 to $7.1822, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:38 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $10.18 | Not disclosed |
DisclosureSEC source: 0000899243-23-002437 · doc4.xml · derivative · entry 2 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-18 F2 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 23:38 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 48,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002437 · doc4.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,985 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 00:39 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 2,015 | $12.45 | $25,089.57 |
DisclosureSEC source: 0000899243-22-034838 · doc4.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,235 F1 · kind: The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.45 to $12.487, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 23:24 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 112,500 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-042083 · doc4.xml · derivative · entry 2 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common stock · 112,500 shares Expires 2031-10-27 F2 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2021 with the remainder vesting thereafter pro-rata in 36 monthly installments. F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2021 with the remainder vesting thereafter pro-rata in 36 monthly installments. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 23:24 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042083 · doc4.xml · nonDerivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| April 06, 2018 Filed Jun 4, 2018 21:55 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-18-038052 · a4.xml · derivative · entry 1 Feder Julie B · CIK 0001710237 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-01-05 F1 · balance_after: On January 5, 2018, the Reporting Person was granted an option to purchase 25,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 5,000 shares. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 22:44 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-18-001509 · a4.xml · derivative · entry 1 Feder Julie B · CIK 0001710237 · CFO, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-05 F1 · derivative.exercise_date: 25% of this option will vest on January 1, 2019 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 1, 2022. Read SEC document |
| July 10, 2017 Filed Jul 11, 2017 20:37 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 370,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-17-044509 · a4.xml · derivative · entry 1 Feder Julie B · CIK 0001710237 · CFO, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,000 Underlying: Common Stock · 370,000 shares Expires 2027-07-10 F1 · derivative.exercise_date: 25% of this option will vest on July 10, 2018 and 6.25% of this option will vest at the end of each successive three-month period thereafter until July 10, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.